Who are the leading innovators in lactobacilli-based drug compositions for the pharmaceutical industry?
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Lactobacilli-based drug compositions.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well-established in the industry.
Innovation S-curve for the pharmaceutical industry
Lactobacilli-based drug compositions is a key innovation area in pharmaceutical
Lactobacillus is usually available as a probiotic. The commonly used commercial strains of lactobacillus are L. acidophilus, L. bulgaricus, L. casei, L. reuteri, and L. GG. It is generally used to treat and prevent diarrhoea such as rotaviral diarrhoea and traveller’s diarrhoea. It is also used to treat other diseases such as irritable bowel syndrome, colic in infants, inflammatory bowel disease (IBD), oral thrush, urinary tract infections (UTIs), and skin infections such as eczema. It helps to break down food, absorb nutrients and fight foreign micro-organisms that cause diseases.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 200+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of lactobacilli-based drug compositions.
Key players in lactobacilli-based drug compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Novo Nordisk Foundation is one of the leading patent filers for lactobacilli-based drug compositions. The company has several lactobacillus-based probiotic products, infant formulas, yogurts, and drinks. The company has also developed a strain that has a significant therapeutic effect on children hospitalised with bacterial diarrhoea that has also shown to prevent nasal congestion in allergic rhinitis.
In terms of application diversity, 4D Pharma is the top company, followed by Spanish National Research Council and Novo Nordisk Foundation. In terms of geographic reach, Spanish National Research Council holds the top position, while 4D Pharma and Giuliani are in the second and third positions, respectively. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
#leading #innovators #lactobacillibased #drug #compositions #pharmaceutical #industry